Skip to NavigationSkip to content

Lilly & Incyte's Olumiant hits main goal in atopic dermatitis

Published on 28/01/20 at 12:27pm

Eli Lilly and Incyte have lifted the curtain on new Phase 3 data showing that their oral JAK inhibitor, showing that the candidate met its primary endpoint in the treatment of atopic dermatitis.

The data concerned Olumiant (baricitinib) in combination with topical corticosteroids (TCS) for the treatment of moderate to severe atopic dermatitis (AD) in adults who were inadequate responders, intolerant or had contraindication to treatment with cyclosporine.

Full results from clinical trials were not revealed, but it was confirmed that the 4mg dose of the drug combined with TCS met its primary endpoint with 29% of patients achieving a change of at least 75% from baseline in the Eczema Area and Severity Index (EASI) at Week 16 compared to placebo.

The drug’s safety profile was also found to be consistent with previous data.  

"There is a high need for additional treatment options for patients living with moderate to severe AD, particularly those who failed conventional systemic treatments like cyclosporine," said Dr Lotus Mallbris, Vice President of Immunology Development at Lilly. "As we look to progress our treatment portfolio for chronic skin conditions, the continued insights from the development programme in AD further the potential of baricitinib to pursue this indication and to reach patients."

Olumiant has already secured approval in over 60 countries to treat moderate to severely  active  rheumatoid arthritis in adult patients.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches